Telferscot Resources Inc. (CSE:TFS) (“Telferscot”) and Canntab Therapeutics Limited (“Canntab”) (and together the “Parties”) are pleased to announce execution of an Amalgamation Agreement (the “Agreement”) between the Parties pursuant to the Agreement. Canntab will amalgamate with a wholly-owned subsidiary of Telferscot and the Canntab shareholders will receive common shares of Telferscot in consideration for their shares of Canntab (the “Amalgamation”).  Canntab has completed its $5-million financing, which was one of the conditions precedent to closing pursuant to the Agreement. The Parties have also satisfied the due diligence set forth in the Agreement and will be filing a listing statement with the Canadian Securities Exchange (“CSE”) for their review, comment and approval.  This Listing Statement will provide detailed disclosure of the new business and related risk factors. The transaction proposed will constitute a Fundamental Change pursuant to CSE policies.

Canntab currently has 4,713,000 common shares outstanding.  With the completion of its private placement Canntab has issued 1,251,914 Subscription Receipts for total gross proceeds of $5,007,656. Immediately prior to the completion of the Amalgamation, each Subscription Receipt will convert in to one Canntab share, resulting in there being 5,964,914 common shares of Canntab.  Pursuant to the Amalgamation, shareholders of Canntab will receive 4 post-consolidation shares of Telferscot for each share of Canntab. Telferscot Shareholders are being asked to approve a consolidation of Telferscot Common Shares on a basis of 1 post-consolidation share for every 200 current, pre-consolidation shares (the “Consolidation”).  Following the Consolidation, Telferscot will have approximately 574,284 shares and 50,750 options outstanding.  Pursuant to the Amalgamation, Telferscot will issue 23,859,656 shares, 1,520,800 warrants and 1,880,000 options to the security holders of Canntab.

“We are pleased with the progress of the transaction. Closing the recent Canntab financing ensures that the future of Canntab and its business plan will be well funded upon completion of the current transaction,” said Stephen Coates, President and CEO of Telferscot.

“Completing the reverse takeover of Telferscot is a major stepping stone for Canntab. Obtaining a public listing will provide liquidity to our shareholders and a platform for us to continue building our base of extended release tablets and other formulations which are ready to go to market globally,” said Richard Goldstein, Co-Founder and CFO of Canntab.

It is expected that Telferscot will obtain shareholder approval of the transaction along with the proposed consolidation of shares and company name change at a meeting of shareholders to be held as soon as practicable.  Additionally, and upon the successful completion of the transaction, Telferscot will be spinning out the current legal action, which it is pursuing against Auxico Resources Inc., as well as several business transactions that Telferscot was pursuing at the time of reaching agreement with Canntab.  Further information on the spinout assets and related actions will be provided to shareholders in due course.

About Canntab Therapeutics Limited
Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

About Telferscot Resources Inc.
Telferscot Resources Inc. is a Canadian company listed on the CSE under ticker symbol TFS. For further information and access to the Company’s public disclosure record please consult SEDAR at or the Canadian Securities Exchange at

This news release may contain forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.


Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303

Telferscot Resources Inc.
Catherine Beckett, Manager Corporate Affairs
Office: 416-642-1807

Click here to connect with Canntab Therapeutics for an Investor Presentation.


Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce the launch of a customer rewards program called “Insider Rewards” for its Urban Juve skin care line.

Cannot view this image? Visit:

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less


  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info:

Keep reading... Show less